Related Experiment Video
Updated: Aug 9, 2026
Freezing Injury in Mouse Masseter Muscle to Establish an Orofacial Muscle Fibrosis Model
Published on: December 29, 2023
Gene therapy with anabolic growth factors to prevent muscle atrophy
Olivier Schakman1, Jean-Paul Thissen
1Department of Diabetology and Nutrition, Catholic University of Louvain, Brussels, Belgium. Olivier.schakman@diab.ucl.ac.be
Purpose Of Review:
Many situations cause muscle atrophy. When severe, muscle atrophy is associated with an increase in morbidity and mortality. This loss of muscle mass is thought to be due to an imbalance between catabolic and anabolic pathways, resulting in an increase of muscle protein proteolysis and in a decrease in protein synthesis. Changes in muscle levels of muscle growth factors are thought to play a major role in this imbalance. Despite recent better understanding of the metabolic and molecular derangements leading to muscle wasting, therapy of muscle atrophy still has a poor success rate.
Recent Findings:
The recent demonstration that changes in local growth factors, such as insulin-like growth factor-I and myostatin, occur during muscle atrophy has stimulated research interest to prevent muscle mass loss by delivering these growth factors or their inhibitors into the muscle. During the last few years, several advances in the field of muscle gene transfer, using electroporation or recombinant adeno-associated viral vectors, have opened novel therapeutic ways to deliver growth factors able to counteract the loss of muscle mass.
Summary:
Preventing decrease of insulin-like growth factor-I muscle, or inhibiting myostatin action by local genes over-expression, may provide a clinically relevant avenue for the preservation, attenuation or reversal of disease-related muscle loss.
Insights
Gene therapy targeting insulin-like growth factor-I and myostatin shows promise for treating muscle atrophy. Local gene overexpression may preserve or reverse muscle loss, offering a new therapeutic approach for this condition.
Area of Science:
- Muscle physiology and molecular biology
- Regenerative medicine
- Gene therapy applications
Background:
- Muscle atrophy, a severe condition linked to increased morbidity and mortality, results from an imbalance in muscle protein synthesis and breakdown.
- Alterations in muscle growth factors are implicated in the catabolic-anabolic pathway derangements leading to muscle wasting.
- Current therapies for muscle atrophy have limited success despite advances in understanding its molecular basis.
Purpose of the Study:
- To explore novel therapeutic strategies for muscle atrophy by targeting key muscle growth factors.
- To investigate the potential of gene transfer methods for delivering therapeutic agents to counteract muscle mass loss.
Main Methods:
- Utilizing advances in muscle gene transfer, including electroporation and recombinant adeno-associated viral vectors.
- Focusing on modulating local growth factors like insulin-like growth factor-I and myostatin.
Main Results:
- Demonstrated that changes in local growth factors, specifically insulin-like growth factor-I and myostatin, are associated with muscle atrophy.
- Gene transfer techniques offer novel methods for delivering growth factors or inhibitors to prevent muscle mass reduction.
Conclusions:
- Local gene overexpression to increase insulin-like growth factor-I or inhibit myostatin presents a promising clinical strategy.
- These gene-based approaches may offer a viable means to preserve, attenuate, or reverse disease-related muscle loss.
Related Concept Videos
01:21Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
01:21Satellite Stem Cells and Muscular Dystrophy
00:59Gene Therapy
01:26Cellular Adaptation II: Hypertrophy
02:38Mitogens and the Cell Cycle
01:26Cross-bridge Cycle